Preclinical pharmacokinetics of radiolabelled hyaluronan

. 2012 ; 64 (2) : 428-37.

Jazyk angličtina Země Švýcarsko Médium print

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid22661195
Odkazy

PubMed 22661195
DOI 10.1016/s1734-1140(12)70784-3
PII: S1734-1140(12)70784-3
Knihovny.cz E-zdroje

BACKGROUND: Hyaluronan (HYA) is a high molecular weight glucosaminoglycan with a great perspective for medical applications. Because HYA is widespread in the body, it is difficult to determine the fate of exogenously administered HYA. METHODS: In this study, HYAof different molecular weights (0.1-1 MDa) was labelled with (99m)Tc, and the distribution profiles were determined after administrating the HYA to rats. RESULTS: After the intravenous administration of (99m)Tc-HYA, a rapid decrease in the radioactivity of blood samples was observed, presumably because of (99m)Tc-HYA uptake by the liver; only minimal signs of liver radioactivity washout were detected. After the oral administration of (99m)Tc-HYA, no significant absorption to the central compartment was found. A preliminary study using (14)C-HYA exhibited a different distribution profile than (99m)Tc-HYA because of the different administered dose and the fate of the degradation products. Even with (14)C-HYA, only traces of radioactivity were absorbed after oral administration. CONCLUSION: This paper provides quantitative information regarding the distribution parameters of radiolabelled HYA in preclinical experiments.

Citace poskytuje Crossref.org

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...